Moderna shares plunge after cancer vaccine data leaks
CNBC · RSS · · AI-summarised by FinFlash
Moderna released full data on its closely watched cancer vaccine developed with Merck, after the results leaked ahead of schedule. Shares fell sharply despite the underlying results being positive, with the disclosure process rather than the science driving the selloff. For investors, the reaction shows how sensitive Moderna's valuation is to trial data timing and how it reaches the market.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.